FLT3 and acute myeloid leukemia: Results from a phase 2 study assessing quizartinib as monotherapy comparing two different dosing scheduled confirm a high degree of antileukemic activity of quizartinib in FLT3-ITD positive AML patients with half of included patients achieving a hematological response, and as many as 33% of patients were successfully bridged to hematological stem cell transplantation [62].